Dr. Bo Dai: Research Progress in ASCO-GU 2023 prostate cancer

Dr. Bo Dai: Research Progress in ASCO-GU 2023 prostate cancer

2024.01.18
The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium for 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. Numerous innovative treatment studies have emerged in the fields of metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and early/localized prostate cancer. These studies encompass a wide range of therapies, including androgen deprivation therapy (ADT), novel hormonal therapy (NHT), PARP inhibitors (PARPi), immunotherapy, nuclear medicine therapy, and localized treatments.
ESMO 2023 | Dr. Oliver Sartor: Lu-PSMA therapy could benefit mCRPC patients

ESMO 2023 | Dr. Oliver Sartor: Lu-PSMA therapy could benefit mCRPC patients

2023.11.06
Prostate cancer remains a significant health concern, especially in its metastatic castration-resistant form, which poses a formidable challenge for both patients and healthcare providers. Despite ongoing advancements in treatment options, the battle against this deadly disease continues. However, recent research has illuminated a ray of hope through the use of PSMA Lutetium therapy. In this article, we delve into the insights presented by Dr. Oliver Sartor at ESMO 2023 regarding the safety, efficacy, and potential benefits of PSMA Lutetium therapy in the treatment of metastatic castration-resistant prostate cancer.
Dr. Bo Dai: Research Progress in ASCO-GU 2023 prostate cancer

Dr. Bo Dai: Research Progress in ASCO-GU 2023 prostate cancer

2023.10.13
The American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium for 2023 (ASCO-GU 2023) kicked off on February 16th in San Francisco, USA. Numerous innovative treatment studies have emerged in the fields of metastatic hormone-sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer (nmCRPC), and early/localized prostate cancer. These studies encompass a wide range of therapies, including androgen deprivation therapy (ADT), novel hormonal therapy (NHT), PARP inhibitors (PARPi), immunotherapy, nuclear medicine therapy, and localized treatments.